Medicinal, Psychological, and Health Research Journal (MPHRJ)

Prognostic Value and Predictive Utility of CA15 3 and CRP as Pathophysiological Biomarkers in Patients with Breast Cancer Undergoing Chemotherapy

Document Type : Original Article

Authors

Parisa Mehrasa 1
Reza Eghdam Zamiri 2

1 Assistant Professor of Pathology, Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

2 Associate Professor of Radiology, Department of Radiology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

10.22034/mphrj.2026.586290.1100
Abstract
Introduction: Breast cancer outcomes vary widely, creating a need for accessible biomarkers that reflect tumor burden and systemic inflammation during chemotherapy. CA15 3 and CRP may provide complementary prognostic and predictive information. This study aims to evaluate the prognostic value and predictive utility of CA15 3 and CRP in patients with breast cancer undergoing chemotherapy.

Material and methods: This descriptive cross-sectional study will be conducted at Shahid Madani Hospital, Tabriz University of Medical Sciences, using convenience sampling to enroll 70 breast cancer patients undergoing chemotherapy. Demographic, clinicopathological, and treatment data, along with serum CA15-3 and CRP levels, will be collected and analyzed using appropriate descriptive and inferential statistics.

Results: In 70 patients with breast cancer undergoing chemotherapy, the mean age was 49.8 ± 10.7 years; 80.0% had invasive ductal carcinoma, 70.0% had lymph node involvement, and 18.6% had metastasis. Median CA15-3 and CRP levels were 31.5 U/mL and 8.9 mg/L, respectively.

Conclusion: These findings indicate that CA15-3 and CRP reflect related but non-identical biological dimensions in patients with breast cancer undergoing chemotherapy. While CA15-3 appears to represent tumor-associated activity, CRP likely captures the accompanying systemic inflammatory response.

Graphical Abstract

Prognostic Value and Predictive Utility of CA15 3 and CRP as Pathophysiological Biomarkers in Patients with Breast Cancer Undergoing Chemotherapy

Keywords

Breast cancer
CA15-3
C-reactive protein
Chemotherapy
Biomarkers
Subjects
[1]                Hashemloo, A and Milanifard, M. (2025). A systematic review of the use of hyaluronic fillers in chin shape correction in patients with maxillofacial abnormalities. Medicinal, Psychological, and Health Research Journal (MPHRJ), 2(1), 1-9.
[2]    Aryee, M. J., Jaffe, A. E., Corrada-Bravo, H., Ladd-Acosta, C., Feinberg, A. P., Hansen, K. D., & Irizarry, R. A. (2014). Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics, *30*(10), 1363–1369.
[3]    Bertucci, F., Ueno, N. T., Finetti, P., Vermeulen, P., Lucci, A., Robertson, F. M., ... & Birnbaum, D. (2014). Gene expression profiles of inflammatory breast cancer: Correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Annals of Oncology, *25*(2), 358–365.
[4]    Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., ... & Xu, L. (2019). Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. Signal Transduction and Targeted Therapy, *4*(1), 62.
[5]    Do Canto, L. M., Barros-Filho, M. C., Rainho, C. A., & Rogatto, S. R. (2020). Comprehensive analysis of DNA methylation and prediction of response to neoadjuvant therapy in locally advanced rectal cancer. Cancers (Basel), *12*(11), 3079.
[6]    Faldoni, F. L. C., Rainho, C. A., & Rogatto, S. R. (2020). Epigenetics in inflammatory breast cancer: Biological features and therapeutic perspectives. Cells, *9*(5), 1164.
[7]    Faldoni, F. L. C., Villacis, R. A. R., Canto, L. M., de Souza, J. B. M., Queiroz, J. S., Delmiro, M. C., ... & Rogatto, S. R. (2020). Inflammatory breast cancer: Clinical implications of genomic alterations and mutational profiling. Cancers, *12*(10), 2816.
[8]    Gillman, A. S., Gardiner, C. K., Koljack, C. E., Bryan, A. D., & Hutchison, K. E. (2018). Body mass index, diet, and exercise: Testing possible linkages to breast cancer risk via DNA methylation. Breast Cancer Research and Treatment, *168*(1), 241–248.
[9]    Gu, Z., Eils, R., & Schlesner, M. (2016). Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics, *32*(18), 2847–2849.
[10] Lim, B., Woodward, W. A., Wang, X., Reuben, J. M., & Ueno, N. T. (2018). Inflammatory breast cancer biology: The tumour microenvironment is key. Nature Reviews Cancer, *18*(8), 485–499.
[11] Ross, J. S., Ali, S. M., Wang, K., Khaira, D., Palma, N. A., Chmielecki, J., ... & Stephens, P. J. (2015). Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Research and Treatment, *154*(1), 155–162.
[12]  Rezaei,M and Eghdam Zamiri,R . (2026). Concurrent COVID‑19 Infection and Chemotherapy in Patients With Cancer and Its Impact on Thrombectomy‑Related Outcomes. Medicinal, Psychological, and Health Research Journal (MPHRJ), 2(1), 61-64.
[13] Schairer, C., Laurent, C. A., Moy, L. M., Gierach, G. L., Falk, R. T., Stanczyk, F. Z., ... & Brinton, L. A. (2020). Obesity and related conditions and risk of inflammatory breast cancer: A nested case-control study. Breast Cancer Research and Treatment, *183*(2), 467–478.
[14] Teschendorff, A. E., Marabita, F., Lechner, M., Bartlett, T., Tegner, J., Gomez-Cabrero, D., & Beck, S. (2013). A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics, *29*(2), 189–196.
[15] Van der Auwera, I., Yu, W., Suo, L., Van Neste, L., van Dam, P., Van Marck, E. A., ... & Vermeulen, P. B. (2010). Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS ONE, *5*(9), e12616.
[16] van Uden, D. J., van Laarhoven, H. W., Westenberg, A. H., de Wilt, J. H., & Blanken-Peeters, C. F. (2015). Inflammatory breast cancer: An overview. Critical Reviews in Oncology/Hematology, *93*(2), 116–126.
[17] Van Laere, S. J., Ueno, N. T., Finetti, P., Vermeulen, P., Lucci, A., Robertson, F. M., ... & Bertucci, F. (2013). Uncovering the molecular secrets of inflammatory breast cancer biology: An integrated analysis of three distinct Affymetrix gene expression datasets. Clinical Cancer Research, *19*(17), 4685–4696.
[18] Woodward, W. A., Krishnamurthy, S., Yamauchi, H., El-Zein, R., Ogura, D., Kitadai, E., ... & Ueno, N. T. (2013). Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Research and Treatment, *138*(3), 761–772.
[19] Zare, A., Postovit, L. M., & Githaka, J. M. (2021). Robust inflammatory breast cancer gene signature using nonparametric random forest analysis. Breast Cancer Research, *23*(1), 92.
Medicinal, Psychological, and Health Research Journal (MPHRJ)
Volume 2, Issue 5
September and October 2026
Pages 329-338

Home

Editorial Board

Guide for Authors

Submit Manuscript

Contact Us